Clonal dominance defines metastatic dissemination in pancreatic cancer.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
15 Mar 2024
Historique:
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 13 3 2024
Statut: ppublish

Résumé

Tumors represent ecosystems where subclones compete during tumor growth. While extensively investigated, a comprehensive picture of the interplay of clonal lineages during dissemination is still lacking. Using patient-derived pancreatic cancer cells, we created orthotopically implanted clonal replica tumors to trace clonal dynamics of unperturbed tumor expansion and dissemination. This model revealed the multifaceted nature of tumor growth, with rapid changes in clonal fitness leading to continuous reshuffling of tumor architecture and alternating clonal dominance as a distinct feature of cancer growth. Regarding dissemination, a large fraction of tumor lineages could be found at secondary sites each having distinctive organ growth patterns as well as numerous undescribed behaviors such as abortive colonization. Paired analysis of primary and secondary sites revealed fitness as major contributor to dissemination. From the analysis of pro- and nonmetastatic isogenic subclones, we identified a transcriptomic signature able to identify metastatic cells in human tumors and predict patients' survival.

Identifiants

pubmed: 38478609
doi: 10.1126/sciadv.add9342
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadd9342

Auteurs

I-Lin Ho (IL)

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Chieh-Yuan Li (CY)

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Fuchenchu Wang (F)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Li Zhao (L)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jingjing Liu (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Er-Yen Yen (EY)

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Charles A Dyke (CA)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Rutvi Shah (R)

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Zhaoliang Liu (Z)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ali Osman Çetin (AO)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Str. 10, 13125 Berlin, Germany.

Yanshuo Chu (Y)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Francesca Citron (F)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sergio Attanasio (S)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Denise Corti (D)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Faezeh Darbaniyan (F)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Edoardo Del Poggetto (E)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sara Loponte (S)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jintan Liu (J)

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Melinda Soeung (M)

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ziheng Chen (Z)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Shan Jiang (S)

TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Hong Jiang (H)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Akira Inoue (A)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sisi Gao (S)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Angela Deem (A)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ningping Feng (N)

TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Haoqiang Ying (H)

Department of Cellular and Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Michael Kim (M)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Virginia Giuliani (V)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Str. 10, 13125 Berlin, Germany.

Giannicola Genovese (G)

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jianhua Zhang (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Andrew Futreal (A)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Anirban Maitra (A)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Timothy Heffernan (T)

TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Linghua Wang (L)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Kim-Anh Do (KA)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Gaetano Gargiulo (G)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Str. 10, 13125 Berlin, Germany.

Giulio Draetta (G)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Alessandro Carugo (A)

TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ruitao Lin (R)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Andrea Viale (A)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Classifications MeSH